SCHEMBL1279487

SCHEMBL1279487

C[C@H]1OC(Oc2c(O)cc3c(=O)oc4c(O)c(O)cc5c(=O)oc2c3c45)[C@@H](O)[C@@H](O)[C@@H]1O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.54
KDM4E B2RXH2 4/20 0.54
CA12 O43570 4/20 0.54
RECQL P46063 3/20 0.54
TDP1 Q9NUW8 3/20 0.54
POLB P06746 3/20 0.54
GAA P10253 3/20 0.54
MEN1 O00255 3/20 0.54
HPGD P15428 3/20 0.54
KMT2A Q03164 3/20 0.54
AKR1B1 P15121 3/20 0.54
MAOA P21397 3/20 0.54
EPHX2 P34913 3/20 0.54
CA7 P43166 3/20 0.54
CA9 Q16790 3/20 0.54
APEX1 P27695 2/20 0.54
BLM P54132 2/20 0.54
CA2 P00918 2/20 0.54
CA4 P22748 2/20 0.54
CA1 P00915 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Eschweilenol C SCHEMBL1699342 0.88 KDM4E (0.54) MAPTKDM4ECA12RECQLTDP1
Eschweilenol C SCHEMBL15359344 0.88 KDM4E (0.54) MAPTKDM4ECA12RECQLTDP1
SCHEMBL1444961 0.85 SOST (0.60) MAPTKDM4ECA12RECQLTDP1
SCHEMBL1279584 0.85 SOST (0.60) MAPTKDM4ECA12RECQLTDP1
SCHEMBL1279902 0.84 SOST (0.59) MAPTKDM4ECA12RECQLTDP1
SCHEMBL1279510 0.81 MAPT (0.54) MAPTKDM4ECA12RECQLTDP1
SCHEMBL31237905 0.76 CA12 (0.52) MAPTKDM4ECA12RECQLTDP1
SCHEMBL30658623 0.76 RELA (0.60) MAPTKDM4ECA12RECQLTDP1
SCHEMBL2355138 0.76 KDM4E (0.88) MAPTKDM4ECA12RECQLTDP1
SCHEMBL2369012 0.75 KDM4E (0.77) MAPTKDM4ECA12RECQLTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9351492-B2 Anti-biofilm compositions and methods for using BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) 2016-05-31 US claimed
US-20140271777-A1 ANTI-BIOFILM COMPOSITIONS AND METHODS FOR USING BOARD OF TRUSTEES UNIVERSITY OF ARKANSAS (US) 2014-09-18 US claimed
US-8741855-B2 Anti-biofilm compositions and methods for using THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) 2014-06-03 US claimed
EP-2624702-A2 ANTI-BIOFILM COMPOSITIONS AND METHODS FOR USING The Board of Trustees of The University of Arkansas (US) 2013-08-14 EP claimed
US-20120088671-A1 ANTI-BIOFILM COMPOSITIONS AND METHODS FOR USING BOARD OF TRUSTEES UNIVERSITY OF ARKANSAS (US) 2012-04-12 US claimed
WO-2012048119-A2 ANTI-BIOFILM COMPOSITIONS AND METHODS FOR USING THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) 2012-04-12 WO claimed
US-9351492-B2 Anti-biofilm compositions and methods for using BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) 2016-05-31 US disclosed
EP-2624702-B1 ANTI-BIOFILM COMPOSITIONS AND METHODS FOR USING UNIV ARKANSAS (US) 2016-03-02 EP disclosed
EP-1734949-B1 PURIFICATIONS OF ELLAGITANNINS UNIV CALIFORNIA (US) 2015-05-20 EP disclosed
US-20140271777-A1 ANTI-BIOFILM COMPOSITIONS AND METHODS FOR USING BOARD OF TRUSTEES UNIVERSITY OF ARKANSAS (US) 2014-09-18 US disclosed
US-8741855-B2 Anti-biofilm compositions and methods for using THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) 2014-06-03 US disclosed
EP-2624702-A2 ANTI-BIOFILM COMPOSITIONS AND METHODS FOR USING The Board of Trustees of The University of Arkansas (US) 2013-08-14 EP disclosed
EP-2481298-A2 USE OF PLANT EXTRACTS AS PREBIOTICS, COMPOSTIONS AND FOODS CONTAINING SUCH EXTRACTS Probelte Pharma, S.A. (ES) 2012-08-01 EP disclosed
US-7638640-B2 total pomegranate tannins (TPT) including punicalagin; nutraceutical for cardiovascular health THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2009-12-29 US disclosed
EP-1734949-A4 PURIFICATIONS OF ELLAGITANNINS UNIV CALIFORNIA (US) 2009-07-22 EP disclosed
US-20080318877-A1 punicalagin extraction; commercial scale; nutraceutical for cardiovascular health NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2008-12-25 US disclosed
EP-1967079-A2 Process and apparatus for preparing pomegranate extracts Probelte Pharma, S.A. (ES) 2008-09-10 EP disclosed
EP-1734949-A1 PURIFICATIONS OF ELLAGITANNINS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2006-12-27 EP disclosed
US-20060211635-A1 total pomegranate tannins (TPT) including punicalagin; nutraceutical for cardiovascular health THE REGENTS OF THE UNIVERSITY OF CLIFORNIA 2006-09-21 US disclosed
WO-2005097106-A1 PURIFICATIONS OF ELLAGITANNINS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2005-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140271777-A1 ANTI-BIOFILM COMPOSITIONS AND METHODS FOR USING TIMP3, MMP13, MMP8 MAPT 3634/4885KDM4E 1528/4885CA12 2383/4885
US-20120088671-A1 ANTI-BIOFILM COMPOSITIONS AND METHODS FOR USING TIMP3, MMP13, MMP8 MAPT 3634/4885KDM4E 1528/4885CA12 2383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.